对CT83的小分子结合物的发现和探索:来自同质模型,虚拟查,MD模拟,交互指纹和网络通信的计算洞察力
Varun Dewaker1, Sung Taek Park1,2,3, Jae Jun Lee1,4
1Institute of New Frontier Research, College of Medicine, Hallym University, Chuncheon-Si, Gangwon-Do 24252, Republic of Korea.
ACS omega
|June 16, 2025
概括
确定了针对基塔-九州肺癌抗原-1 (KK-LC-1) 的新型小分子. CID46375999显示出有希望的结合亲和力和相互作用,使其成为癌症治疗开发的潜在候选人.
科学领域:
- 在瘤学瘤学.
- 计算化学计算化学
- 药物发现 药物发现 药物发现
背景情况:
- 基塔-九州肺癌抗原-1 (KK-LC-1),或CT83,是一种癌症/试管腺抗原 (CTA) 家庭成员.
- 肺癌,胃癌和乳腺癌等癌症的限制表达使CT83成为一个有前途的治疗点.
研究的目的:
- 为了识别针对CT83进行癌症治疗的新型小分子.
- 评估候选分子与CT83.3的结合亲和力和相互作用概况.
主要方法:
- 使用了PubChem搜索,利宾斯基规则过,虚拟选,分子对接和分子动力学 (MD) 模拟.
- 通过Poisson-Boltzmann表面积 (MMPBSA) 计算进行了200 ns的MD模拟和分子力学.
- 分析了相互作用指纹,以了解结合动态和关键残留物相互作用.
主要成果:
- 已经确定了五种候选分子:CID24326943,CID24459131,CID46375999,CID46533890,以及CID55836895.这些分子是最常见的.
- MD模拟证实了稳定的CT83-连接体复合体;Z839878730,CID24459131和CID46375999显示了有利的结合能.
- CID46375999与参考化合物具有很强的相似性,具有1,3,4-thiadiazole-2-carboxamide支架和稳定的相互作用,与关键残留物如Leu15,Phe18和Arg76.
结论:
- 由于其与参考化合物的结构相似性和有利的结合特性,CID46375999成为一个非常有前途的候选物.
- 鉴定的相互作用,包括疏水性,π堆积和键,为CT83抑制剂的结合机制提供了关键的见解.
- 这些发现支持针对表达这种抗原的癌症开发CT83向疗法.
相关概念视频
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
The Equilibrium Binding Constant and Binding Strength
13.9K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
13.9K
Ligand Binding Sites
13.6K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
13.6K
Protein-protein Interfaces
13.8K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.8K
Conserved Binding Sites
4.4K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.4K


